Study Title
Phase II Study of Radionuclide 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With MetastaticCastration Resistant Prostate Cancer (mCRPC)
Study Details
Description:
This phase II study will investigate the activity and safety of radionuclide 177Lu-PSMA therapy versus 177Lu-PSMA in combination with Ipilimumab and Nivolumab in patients with metastatic castrate resistant prostate cancer (mCRPC).
Sponsor:
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Contacts:
Margaret McJannetttrials@anzup.org.au
+61295625033
Izabella Pokorskievolution.study@sydney.edu.au
+61295625000
Government Study Link:
NCT05150236 - Click here to see study onClinicalTrials.gov